PHARMACEUTICAL BIOTECHNOLOGY EXPORT CONTROL: LEGAL AND REGULATORY FRAMEWORK IN INDIA

1. INTRODUCTION

Pharmaceutical biotechnology export control refers to the legal regulation of cross-border movement of biotechnology-derived medicines, biological materials, pharmaceutical manufacturing technologies, research equipment and associated technical information.

The pharmaceutical biotechnology sector includes monoclonal antibodies, recombinant proteins, vaccines, gene therapies, cell therapies, biosimilars, diagnostic products and other biological medicines. Although these products have legitimate medical and commercial applications, certain biological materials, equipment and technologies may also have potential dual-use applications.

India regulates pharmaceutical biotechnology exports through a combination of foreign trade legislation, strategic export-control regulations, pharmaceutical quality standards, customs legislation, environmental biosafety requirements and international non-proliferation commitments.

The principal objective is to facilitate legitimate pharmaceutical exports while preventing unauthorised transfers, diversion of controlled materials and misuse of sensitive biotechnology.

2. PRINCIPAL LEGISLATIVE FRAMEWORK

A. Foreign Trade (Development and Regulation) Act, 1992

This Act provides the statutory foundation for regulating India's foreign trade.

Section 3 empowers the Central Government to regulate, restrict or prohibit imports and exports. Section 5 provides authority for formulating and notifying the Foreign Trade Policy.

The Act also establishes the legal basis for controlling restricted exports and enforcing applicable export authorisation requirements.

B. Foreign Trade Policy, 2023

Chapter 10 governs the export of SCOMET items, meaning Special Chemicals, Organisms, Materials, Equipment and Technologies.

Pharmaceutical biotechnology products may fall within this framework where they meet the technical descriptions of controlled organisms, toxins, materials, equipment or technologies.

SCOMET controls are not automatically applicable to every pharmaceutical or biological product. Classification depends on the notified control-list description and relevant technical characteristics.

C. Weapons of Mass Destruction and their Delivery Systems (Prohibition of Unlawful Activities) Act, 2005

This legislation provides an important national-security framework for preventing the proliferation of weapons of mass destruction.

Its provisions address prohibited activities involving controlled materials, technologies and transfers.

Section 13 specifically addresses restrictions on the transfer of technology relating to controlled items.

D. Customs Act, 1962

The Customs Act provides the enforcement framework for examining export consignments, verifying declarations and preventing unlawful exports.

Section 113 addresses confiscation of goods attempted to be improperly exported, while Section 114 provides for penalties in specified cases of improper export.

E. Drugs and Cosmetics Act, 1940 and Medical Devices Rules, 2017

Pharmaceutical biotechnology products must satisfy applicable manufacturing, quality, licensing and export-related regulatory requirements.

Biological medicines must comply with relevant manufacturing standards, including applicable Good Manufacturing Practices (GMP).

3. SCOMET CLASSIFICATION AND EXPORT AUTHORISATION

SCOMET is India's principal strategic export-control system for specified dual-use goods, software and technologies.

The relevant categories include:

Category 1: Toxic chemical agents and other controlled chemicals.

Category 2: Microorganisms and toxins.

Category 3: Materials, materials-processing equipment and related technologies.

Category 8: Specified special materials, equipment and associated technologies.

Category 2 is particularly relevant to certain biological materials. However, ordinary pharmaceutical ingredients, vaccines and finished biological medicines are not automatically controlled merely because they are biotechnology-derived.

Under the Foreign Trade Policy, 2023, export of listed SCOMET items generally requires DGFT authorisation unless an express exemption or alternative permission applies.

The exporter must examine the applicable technical specifications, classification notes, destination, end-user and intended end-use before shipment.

4. EXPORT LICENSING AND REGULATORY APPROVAL

Companies exporting controlled biotechnology materials must follow the applicable authorisation procedure.

The principal compliance requirements include:

Identify whether the product or technology appears in the applicable SCOMET list.

Determine the relevant technical classification.

Identify the foreign consignee and ultimate end-user.

Obtain applicable end-use and end-user documentation.

Submit the prescribed export authorisation application to DGFT.

Obtain additional regulatory permissions where required.

Ensure that the export matches the conditions of the authorisation.

Maintain shipment and transaction documentation.

The exporter must not assume that an ordinary pharmaceutical export licence automatically satisfies strategic export-control requirements.

5. INTERNATIONAL EXPORT-CONTROL OBLIGATIONS

India's pharmaceutical biotechnology export-control framework is influenced by international non-proliferation commitments.

A. Biological Weapons Convention, 1972

The Convention prohibits the development, production, stockpiling and acquisition of biological and toxin weapons. Its requirements are relevant to preventing the diversion of biological materials and technologies for prohibited purposes.

B. Chemical Weapons Convention, 1993

The Convention regulates chemicals and activities falling within its scope and establishes international controls against chemical weapons.

C. United Nations Security Council Resolution 1540

This resolution requires states to establish appropriate controls to prevent non-state actors from obtaining weapons of mass destruction and related materials.

D. Australia Group

India participates in the Australia Group export-control arrangement. Its control-list developments are relevant to India's strategic export-control alignment.

These international arrangements contribute to India's national export-control policy, but domestic legal obligations arise through applicable Indian legislation and notified regulations.

6. LIABILITY FOR EXPORT-CONTROL VIOLATIONS

Pharmaceutical biotechnology exporters may face serious consequences for non-compliance.

A. Export Without Authorisation

Exporting a controlled SCOMET item without the required authorisation may attract action under the Foreign Trade (Development and Regulation) Act, 1992.

B. False Documentation

Incorrect declarations, misclassification, concealed end-users and false export documentation may result in customs proceedings and other applicable penalties.

C. Unauthorised Technology Transfer

Unauthorised transfers of controlled biotechnology technology may attract the provisions of the WMD Act, 2005, and other relevant legislation.

D. Diversion to Prohibited End-Users

Exporters may face regulatory consequences where controlled materials are diverted to prohibited users or unauthorised military or weapons-related applications.

E. Corporate and Individual Responsibility

Depending on the applicable statute, responsibility may extend to companies and individuals involved in the contravention. Compliance systems should therefore cover directors, export managers, technical personnel, intermediaries and distributors.

7. IMPORTANT JUDICIAL DECISIONS

India has not yet developed a substantial body of Supreme Court decisions specifically addressing pharmaceutical biotechnology export-control violations. The following judgments establish relevant principles of export regulation, customs enforcement, statutory interpretation and biotechnology governance.

1. Om Prakash Bhatia v. Commissioner of Customs (2003) 6 SCC 161 — Direct authority on export-control enforcement.

The Supreme Court examined the meaning of prohibited goods and improper export under customs law. The decision is relevant to exporters making incorrect declarations or attempting to export goods contrary to applicable legal restrictions.

2. Collector of Customs v. D. Bhoormull (1974) 2 SCC 544 — Direct authority on customs enforcement.

The Supreme Court explained the evidentiary principles applicable to customs confiscation proceedings, including the practical burden of establishing facts in cases involving clandestine transactions. This is relevant to investigations involving concealed biotechnology exports.

3. State of Maharashtra v. Mayer Hans George (1965) 1 SCR 123 — Analogous authority on regulatory offences.

The Supreme Court considered the interpretation of foreign-exchange restrictions and the relevance of mens rea in statutory regulatory offences. Its principles are relevant when determining liability for contraventions of export-control legislation.

4. Union of India v. Raj Grow Impex LLP (2021) 18 SCC 392 — Direct authority on export restrictions.

The Supreme Court considered export restrictions and the interpretation of government trade-control measures. The judgment is relevant to understanding the binding nature of notified export-policy conditions.

5. Commissioner of Customs v. Dilip Kumar and Company (2018) 9 SCC 1 — Analogous authority on statutory interpretation.

The Constitution Bench explained principles governing the interpretation of fiscal exemptions. The decision is relevant when exporters rely on claimed exemptions from customs or regulatory requirements, subject to the particular statutory context.

6. Monsanto Technology LLC v. Nuziveedu Seeds Ltd. (2019) 3 SCC 381 — Analogous biotechnology authority.

The Supreme Court considered intellectual-property disputes involving genetically modified seed technology. Although the case did not concern pharmaceutical exports, it illustrates the legal complexities surrounding biotechnology innovations, licensing and commercialisation.

7. Vellore Citizens' Welfare Forum v. Union of India (1996) 5 SCC 647 — Analogous environmental regulatory authority.

The Supreme Court recognised the precautionary principle and polluter-pays principle as important elements of Indian environmental law. These principles are relevant to biotechnology activities involving environmental and biosafety risks.

8. PRACTICAL COMPLIANCE REQUIREMENTS

Pharmaceutical biotechnology exporters should establish a comprehensive export-compliance programme covering:

SCOMET classification and product screening.

DGFT authorisation wherever applicable.

Pharmaceutical manufacturing and quality documentation.

Foreign customer and end-user verification.

Sanctions and restricted-destination screening.

Customs declarations and accurate product descriptions.

Technology-transfer and technical-data controls.

Contractual restrictions on unauthorised re-export.

Shipment traceability and record retention.

Internal audits and employee compliance training.

Particular attention should be given to electronic transfers of controlled technical information, as export-control obligations are not necessarily limited to physical shipments.

9. CONCLUSION

Pharmaceutical biotechnology export control is an important component of India's foreign trade, public health and national-security framework. The Foreign Trade (Development and Regulation) Act, 1992, Foreign Trade Policy, 2023, SCOMET List, WMD Act, 2005, and Customs Act, 1962, collectively establish the principal legal framework.

The central regulatory objective is to protect legitimate pharmaceutical trade while preventing the unauthorised international transfer or diversion of strategically sensitive biological materials and technologies.

Pharmaceutical biotechnology companies must therefore maintain accurate product classification, obtain applicable export permissions, verify foreign end-users and comply with pharmaceutical quality requirements. A robust compliance programme is essential to reducing legal exposure and ensuring responsible international biotechnology trade.